PremiumThe FlyVertex Pharmaceuticals announces MHRA approval of ALYFTREK for CF Vertex non-opioid pain drug picked up by UnitedHealth Vertex Pharmaceuticals: Buy Rating Driven by Outpatient Market Potential and Strategic Initiatives for Journavx PremiumRatingsCautious Hold on Vertex Pharmaceuticals Amid Early-Stage Uncertainty of VX-522 Development Vertex Pharmaceuticals files automatic mixed securities shelf Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb PremiumThe FlyVertex Pharmaceuticals upgraded to Hold from Sell at Canaccord Coca-Cola reports Q4 beat, Elliott discloses Phillips 66 stake: Morning Buzz Vertex Pharmaceuticals price target raised to $450 from $433 at Scotiabank 
